Medable’s AI clinical monitoring software—Clinical Monitoring Agent—showed potential cost and efficiency benefits in an independent analysis led by researchers at Tufts Center for the Study of Drug Development (CSDD). Using Medable data and benchmarking against real-world oncology development inputs, the modeling suggested the tool could help monitors work faster and reduce overall development costs, even though the analysis has not yet been peer-reviewed.